Clinical trial • Phase III • Other
[14C] ABBV-932 for Healthy volunteers
Phase III trial of [14C] ABBV-932 for Healthy volunteers. 8 participants.
Overview
- Trial Therapeutic Area
- Other
- Trial Disease
- Healthy volunteers
- Trial Stage
- Phase III
Key dates
- Initial CTIS Submission Date
- 21-02-2025
- First CTIS Authorization Date
- 25-04-2025
Trial design
Phase III trial across 1 site in Netherlands.
- Target Sample Size
- 8
Eligibility
Recruits 8 No vulnerable population selected. Trial population: Healthy male volunteers only; no specific consent/assent handling described in the record..
- Vulnerable Population
- No vulnerable population selected. Trial population: Healthy male volunteers only; no specific consent/assent handling described in the record.
Recruitment
- Planned Sample Size
- 8
- Recruitment Window Months
- 4
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 8
Netherlands
- Latest Decision Or Authorization Date
- 09-04-2026
- Number Of Sites
- 1
- Number Of Participants
- 8
Sites
- Site Name
- Pharma Bio-Research Group - Van Swietenlaan 6
- Department Name
- Program Management
- Contact Person Name
- Renger Tiessen
- Contact Person Email
- renger.tiessen@iconplc.com
Sponsor
Primary sponsor
- Full Name
- AbbVie Deutschland GmbH & Co. KG
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Germany
Contract research organisations
- Name
- Pharma Bio-Research Group
- Responsibilities
- Program Management; site contact (email: renger.tiessen@iconplc.com)
Investigational products
- Investigational Product Name
- [14C] ABBV-932
Related trials
Other published trials that may interest you.